Anjanappa M, Kumar A, Mathews S, Joseph J, Jagathnathkrishna K M, James F V
Division of Clinical Oncology, Genitourinary Clinic, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
Division of Statistics and Cancer Epidemiology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
Indian J Cancer. 2017 Jan-Mar;54(1):385-387. doi: 10.4103/ijc.IJC_100_17.
This study aims to identify clinical features, treatment outcomes, and prognostic factors for relapse and survival in patients with testicular seminoma.
Retrospective analysis of all patients with pure seminoma treated at our center during over a decade (January 2005-December 2014) was carried out. Patient demographics, tumor characteristics, and treatment details and pattern of recurrence were recorded in a structured format, and disease-free survival and overall survival were calculated.
Sixty-three patients' case records were included in the analysis. Ten patients developed disease in the undescended testis. All patients underwent orchiectomy as the initial treatment procedure. Majority of the patients were Stage I (57.14%) followed by Stage II (39.6%). Among the patients with Stage I, 55.5% received adjuvant chemotherapy while 22.2% received adjuvant radiation and the rest opted for surveillance. The compliance for active surveillance was very poor. Among patients with Stage II disease, majority (80%) were treated with adjuvant chemotherapy and the rest with radiation. At a median follow-up of 49 months, there were four recurrences of which three were salvaged successfully, and one patient remained alive with disease. There were no disease-related deaths.
Testicular seminoma remains to be relatively low and majority of them presented with Stage I disease and single agent carboplatin appeared to be the preferred adjuvant treatment. Advanced disease patients were treated with etoposide and cisplatin/bleomycin, etoposide and cisplatin chemotherapy and the clinical outcome is comparable with the Western literature.
本研究旨在确定睾丸精原细胞瘤患者的临床特征、治疗结果以及复发和生存的预后因素。
对本中心在过去十年（2005年1月至2014年12月）治疗的所有纯精原细胞瘤患者进行回顾性分析。以结构化格式记录患者的人口统计学资料、肿瘤特征、治疗细节和复发模式，并计算无病生存期和总生存期。
63例患者的病例记录纳入分析。10例患者在隐睾中发生疾病。所有患者均接受睾丸切除术作为初始治疗程序。大多数患者为I期（57.14%），其次为II期（39.6%）。在I期患者中，55.5%接受辅助化疗，22.2%接受辅助放疗，其余选择观察。主动观察的依从性很差。在II期疾病患者中，大多数（80%）接受辅助化疗，其余接受放疗。中位随访49个月时，有4例复发，其中3例成功挽救，1例带瘤生存。无疾病相关死亡。
睾丸精原细胞瘤的发病率仍然相对较低，大多数患者表现为I期疾病，单药卡铂似乎是首选的辅助治疗。晚期疾病患者接受依托泊苷和顺铂/博来霉素、依托泊苷和顺铂化疗，临床结果与西方文献相当。
